439 related articles for article (PubMed ID: 21606564)
1. Lipid nanocarriers (GeluPearl) containing amphiphilic lipid Gelucire 50/13 as a novel stabilizer: fabrication, characterization and evaluation for oral drug delivery.
Date AA; Vador N; Jagtap A; Nagarsenker MS
Nanotechnology; 2011 Jul; 22(27):275102. PubMed ID: 21606564
[TBL] [Abstract][Full Text] [Related]
2. Lipid nanocarriers for dermal delivery of lutein: preparation, characterization, stability and performance.
Mitri K; Shegokar R; Gohla S; Anselmi C; Müller RH
Int J Pharm; 2011 Jul; 414(1-2):267-75. PubMed ID: 21596122
[TBL] [Abstract][Full Text] [Related]
3. Studies on binary lipid matrix based solid lipid nanoparticles of repaglinide: in vitro and in vivo evaluation.
Rawat MK; Jain A; Singh S
J Pharm Sci; 2011 Jun; 100(6):2366-78. PubMed ID: 21491449
[TBL] [Abstract][Full Text] [Related]
4. Lipid nanoparticles as vehicles for topical psoralen delivery: solid lipid nanoparticles (SLN) versus nanostructured lipid carriers (NLC).
Fang JY; Fang CL; Liu CH; Su YH
Eur J Pharm Biopharm; 2008 Oct; 70(2):633-40. PubMed ID: 18577447
[TBL] [Abstract][Full Text] [Related]
5. In vivo and cytotoxicity evaluation of repaglinide-loaded binary solid lipid nanoparticles after oral administration to rats.
Rawat MK; Jain A; Singh S
J Pharm Sci; 2011 Jun; 100(6):2406-17. PubMed ID: 21491451
[TBL] [Abstract][Full Text] [Related]
6. Lipid nanoparticles for skin penetration enhancement-correlation to drug localization within the particle matrix as determined by fluorescence and parelectric spectroscopy.
Lombardi Borgia S; Regehly M; Sivaramakrishnan R; Mehnert W; Korting HC; Danker K; Röder B; Kramer KD; Schäfer-Korting M
J Control Release; 2005 Dec; 110(1):151-63. PubMed ID: 16297487
[TBL] [Abstract][Full Text] [Related]
7. Development and evaluation of lipid nanoparticles for camptothecin delivery: a comparison of solid lipid nanoparticles, nanostructured lipid carriers, and lipid emulsion.
Huang ZR; Hua SC; Yang YL; Fang JY
Acta Pharmacol Sin; 2008 Sep; 29(9):1094-102. PubMed ID: 18718178
[TBL] [Abstract][Full Text] [Related]
8. Nanostructured lipid carriers (NLC) on the basis of Siberian pine (Pinus sibirica) seed oil.
Averina ES; Seewald G; Müller RH; Radnaeva LD; Popov DV
Pharmazie; 2010 Jan; 65(1):25-31. PubMed ID: 20187575
[TBL] [Abstract][Full Text] [Related]
9. Preparation and characterization of nanostructured lipid carriers loaded traditional Chinese medicine, zedoary turmeric oil.
Zhao XL; Yang CR; Yang KL; Li KX; Hu HY; Chen DW
Drug Dev Ind Pharm; 2010 Jul; 36(7):773-80. PubMed ID: 20136496
[TBL] [Abstract][Full Text] [Related]
10. Stability of lipid excipients in solid lipid nanoparticles.
Radomska-Soukharev A
Adv Drug Deliv Rev; 2007 Jul; 59(6):411-8. PubMed ID: 17553589
[TBL] [Abstract][Full Text] [Related]
11. Investigation of surface-modified solid lipid nanocontainers formulated with a heterolipid-templated homolipid.
Attama AA; Müller-Goymann CC
Int J Pharm; 2007 Apr; 334(1-2):179-89. PubMed ID: 17140752
[TBL] [Abstract][Full Text] [Related]
12. Characterization of indomethacin-loaded lipid nanoparticles by differential scanning calorimetry.
Castelli F; Puglia C; Sarpietro MG; Rizza L; Bonina F
Int J Pharm; 2005 Nov; 304(1-2):231-8. PubMed ID: 16188405
[TBL] [Abstract][Full Text] [Related]
13. Effect of drug solubility and lipid carrier on drug release from lipid nanoparticles for dermal delivery.
Zoubari G; Staufenbiel S; Volz P; Alexiev U; Bodmeier R
Eur J Pharm Biopharm; 2017 Jan; 110():39-46. PubMed ID: 27810471
[TBL] [Abstract][Full Text] [Related]
14. Lipid nanoparticles with different oil/fatty ester ratios as carriers of buprenorphine and its prodrugs for injection.
Wang JJ; Liu KS; Sung KC; Tsai CY; Fang JY
Eur J Pharm Sci; 2009 Sep; 38(2):138-46. PubMed ID: 19591929
[TBL] [Abstract][Full Text] [Related]
15. Polyhydroxy surfactants for the formulation of lipid nanoparticles (SLN and NLC): effects on size, physical stability and particle matrix structure.
Kovacevic A; Savic S; Vuleta G; Müller RH; Keck CM
Int J Pharm; 2011 Mar; 406(1-2):163-72. PubMed ID: 21219990
[TBL] [Abstract][Full Text] [Related]
16. Enhancement in antifungal activity of eugenol in immunosuppressed rats through lipid nanocarriers.
Garg A; Singh S
Colloids Surf B Biointerfaces; 2011 Oct; 87(2):280-8. PubMed ID: 21689909
[TBL] [Abstract][Full Text] [Related]
17. Characterization and formulation optimization of solid lipid nanoparticles in vitamin K1 delivery.
Liu CH; Wu CT; Fang JY
Drug Dev Ind Pharm; 2010 Jul; 36(7):751-61. PubMed ID: 20136495
[TBL] [Abstract][Full Text] [Related]
18. Effects of gelucire content on stability, macrophage interaction and blood circulation of nanoparticles engineered from nanoemulsions.
Wehrung D; Geldenhuys WJ; Oyewumi MO
Colloids Surf B Biointerfaces; 2012 Jun; 94():259-65. PubMed ID: 22386863
[TBL] [Abstract][Full Text] [Related]
19. Solid lipid nanodispersions containing mixed lipid core and a polar heterolipid: characterization.
Attama AA; Schicke BC; Paepenmüller T; Müller-Goymann CC
Eur J Pharm Biopharm; 2007 Aug; 67(1):48-57. PubMed ID: 17276663
[TBL] [Abstract][Full Text] [Related]
20. In vivo real-time fluorescence visualization and brain-targeting mechanisms of lipid nanocarriers with different fatty ester:oil ratios.
Wen CJ; Yen TC; Al-Suwayeh SA; Chang HW; Fang JY
Nanomedicine (Lond); 2011 Nov; 6(9):1545-59. PubMed ID: 22077462
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
